

NephroCare Health Services (NEPHROPLUS) – Recommended Stock – Target Achieved

Dear Bajaj Capital Investors,

We are pleased to inform you that **Bajaj Capital's Research Team**—recommended stock, **NephroCare Health Services Limited (NephroPlus)** has successfully achieved our target price of 735 on 8 Sept 2026.

Notably, the **stock delivered a return of 15% (CMP is 736 as of 8 Sept 2026) within 2 months of investment duration from our recommendation**, significantly outperforming our envisaged 6 to 9 months investment horizon.

Investment View: We advise investors to **HOLD NephroCare Health Services Ltd. stock at current levels**. We will share our updated outlook and strategy in the coming weeks.

Recommendation Timeline & Performance Summary: -

1. 9 July 2026 – Initial BUY Recommendation: The BUY call was initiated at a price of 640 with a target price of 735, implying an upside potential of 15% over a 6 to 9 months investment horizon.

2. 8 Sept 2026 – Target Achieved: The stock achieved our target price of 735 on 8 Sept 2026 and delivered a return of 15% (CMP is 736 as of 8 Sept 2026) within 2 months of investment duration from our recommendation, significantly ahead of our envisaged 6 to 9 months investment horizon.

Happy Investing!

Thank you and best regards,

On behalf of Bajaj Capital's Research Team